Researchers develop noninvasive method to detect early-stage liver disease

A safer and more sensitive contrast dye for MRI tests may provide the first effective, noninvasive method for detecting and diagnosing early-stage liver diseases, including liver fibrosis. Tests in animal models show the protein-based contrast agent, ProCA32.collagen1, can detect the early stage of alcohol-induced liver fibrosis and Non-Alcoholic SteatoHepatitis, which is the most severe form of non-alcohol fatty liver disease.